
-
Palatin Technologies NYSE MKT LLC:PTN Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.
Location: 4B Cedarbrook Dr, New Jersey, 08512-3641, US | Website: www.palatin.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.662M
Cash
3.417M
Avg Qtr Burn
-6.736M
Short % of Float
9.95%
Insider Ownership
2.63%
Institutional Own.
14.18%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Vyleesi® (bremelanotide) MC4r Agonist Details Sexual dysfunction, Sexual desire disorder, Influenza | Approved Quarterly sales | |
PL9643 Details Dry eye syndrome, Eye disease | Phase 3 Data readout | |
Bremelanotide + PDE5i Details Erectile dysfunction
| Phase 2 Data readout | |
Bremelanotide Details Diabetic Kidney Disease | Phase 2 Update | |
PL8177 oral formulation Details Chronic inflammatory disorder, Inflammatory disease, Bowel disorder, Ulcerative colitis | Phase 2 Update | |
Bremelanotide + Tirzepatide Details Obesity, Metabolic disorder | IND Submission | |
PL8177 Details Eye disease , Inflammatory disease | Failed Discontinued | |
PL3994 (NPR-A agonist) Details Heart disease | Failed Discontinued | |
PL8177 Details COVID-19 | Failed Discontinued |